Filings & corporate actions
- 14 NovresultsResults · Q2 FY27 · consolidated and standalone+4.5%NSE
- 17 OctshareholdingShareholding · 30 Sept 2026-1.9%NSE
- 3 OctshareholdingShareholding · 1 Aug 2026-2.4%NSE
- 14 AugresultsResults · Q1 FY27 · consolidated and standalone-4.5%NSE
- 14 AugresultsResults · Q4 FY26 · consolidated and standalone-4.5%NSE
- 21 JulshareholdingShareholding · 30 Jun 2026-2.3%NSE
- 25 MayresultsResults · Q4 FY26 · consolidated and standalone+1.3%NSE
- 20 AprshareholdingShareholding · 31 Mar 2026-4.2%NSE
- 11 FebresultsResults · Q3 FY26 · consolidated and standalone-2.6%NSE
- 21 JanshareholdingShareholding · 31 Dec 2025-0.7%NSE
Reaction to results · all yearsrose on day 0 in 11 of 25 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q2 FY27 | 14 Nov 2026 | +4.5% | — | — | 11.5× |
| Q1 FY27 | 14 Aug 2026 | -4.5% | -0.7% | -5.5% | 2.8× |
| Q4 FY26 | 25 May 2026 | +1.3% | +17.0% | +38.9% | 1.5× |
| Q3 FY26 | 11 Feb 2026 | -2.6% | -2.9% | -25.8% | 4.2× |
| Q2 FY26 | 11 Nov 2025 | -1.3% | +3.5% | +1.4% | 5.1× |
| Q1 FY26 | 12 Aug 2025 | +1.2% | +3.5% | -6.4% | 1.3× |
| Q4 FY25 | 28 May 2025 | -5.0% | +2.8% | -0.1% | 4.1× |
| Q3 FY25 | 13 Feb 2025 | -15.2% | -29.1% | -34.7% | 10.5× |
| Q2 FY25 | 12 Nov 2024 | +2.0% | +1.7% | +17.0% | 1.8× |
| Q1 FY25 | 13 Aug 2024 | -1.5% | -2.2% | +7.5% | 0.5× |
| Q4 FY24 | 24 May 2024 | -0.2% | -2.9% | +16.3% | 1.3× |
| Q3 FY24 | 10 Feb 2024 | +3.1% | +9.1% | +2.4% | 2.5× |
| Q2 FY24 | 5 Nov 2023 | +1.9% | +10.2% | +17.5% | 1.7× |
| Q1 FY24 | 11 Aug 2023 | -4.9% | -6.6% | -8.6% | 1.0× |
| Q4 FY23 | 11 May 2023 | +4.9% | +2.2% | +0.5% | 4.0× |
| Q3 FY23 | 10 Feb 2023 | +3.5% | +9.5% | +4.5% | 3.6× |
| Q2 FY23 | 15 Nov 2022 | 0.0% | -4.1% | -9.2% | 0.7× |
| Q1 FY23 | 10 Aug 2022 | -1.0% | -1.5% | +6.8% | 1.0× |
| Q4 FY22 | 13 May 2022 | +0.4% | -4.3% | -6.5% | 0.3× |
| Q3 FY22 | 13 Feb 2022 | -2.1% | -9.3% | -8.9% | 1.7× |
| Q2 FY22 | 15 Nov 2021 | -1.0% | -6.0% | -5.4% | 0.5× |
| Q1 FY22 | 14 Aug 2021 | -4.7% | -10.0% | -2.2% | 0.4× |
| Q4 FY21 | 23 May 2021 | -0.3% | -3.8% | -6.4% | 0.7× |
| Q3 FY21 | 10 Feb 2021 | +5.0% | +34.0% | +178.4% | 4.2× |
| Q2 FY21 | 12 Nov 2020 | +5.0% | +39.9% | +188.6% | — |
| Average | -0.5% | +2.1% | +15.0% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q2 FY27
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +16.2% | +17.6% | +17.7% | +22.5% | — | — |
| Profit | -38.5% | -22.3% | — | — | — | — |
Key data
Delivery percentage
Over the last 20 sessions ORCHPHARMA settled 43.3% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 47.8%, so recent sessions are running 4.5 points lower than usual. The latest session ranks higher than 23% of the 1,495 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
Dividends, deals & holders
Performance returns
| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +1.24% | +8.59% | +9.69% | -2.00% | +35.74% | +19.50% |
Valuation
Ownership
Quarterly results · consolidated
| Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 207.3 | 368.3 | 304.2 | 341.3 |
| YoY chg | -4.6% | +55.1% | +75.9% | +76.3% |
| Net profit (₹ Cr) | (12.6) | 25.8 | 3.2 | 28.6 |
| YoY chg | -160.7% | +15.9% | -78.4% | — |
| Net margin | -6.1% | 7.0% | 1.1% | 8.4% |
| EPS | -2.49 | 4.31 | 0.54 | 4.77 |
Shareholding over time
By quarter
30 Sept 2026 · promoter 74.45% · public 25.55%- Promoter
- Public and others
- Promoter
- 74.45%
- Public
- 25.55%
- Promoter change
- 0.00 pp
- Filed
- 17 Oct 2026
- FII
- 0.93%
- DII
- 17.44%
- Promoter pledged
- 0.00%
Who the public is
- Mutual funds
- 16.88%
- Insurance
- 0.01%
- FPI
- 0.93%
- Retail ≤ ₹2L
- 4.49%
- HNI > ₹2L
- 0.76%
- NRI
- 0.35%
- Bodies corporate
- 1.34%
- Shareholders
- 33,790
-0.02 pp QoQ
0.00 pp QoQ
+0.01 pp QoQ
+0.13 pp QoQ
-0.01 pp QoQ
0.00 pp QoQ
+0.01 pp QoQ
+1.6% QoQ
Major holders
As of 30 Sept 2026| Holder | Type | Holding | Shares |
|---|---|---|---|
| Triveni Trust | Promoter · Other | 32.62% | 1.95Cr |
| MANISH DHANUKA | Promoter · Individual | 10.94% | 65.53L |
| Pushpa Dhanuka Trust | Promoter · Other | 9.68% | 57.95L |
| QUANT MUTUAL FUND - QUANT SMALL CAP FUND | Mutual fund | 5.79% | 34.66L |
| MAMTA DHANUKA | Promoter · Individual | 5.20% | 31.17L |
| ARJUN DHANUKA | Promoter · Individual | 4.82% | 28.86L |
| KOTAK MAHINDRA TRUSTEE CO LTD AND 6 OTHERS WITH SAME PAN | Mutual fund | 3.99% | 23.87L |
| UMA DHANUKA | Promoter · Individual | 3.15% | 18.84L |
| PUSHPA DHANUKA | Promoter · Individual | 3.09% | 18.52L |
| UTI VALUE FUND AND 3 OTHERS WITH SAME PAN | Mutual fund | 3.09% | 18.51L |
Every promoter-group member, and each public holder above 1%, as filed.
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.
Insider trades
- Insiders net, 30d
- ₹0
- Insiders net, 90d
- ₹0
- Promoters net, 90d
- ₹0
- Insider buyers, 90d
- 0
- Last promoter buy
- none on record
- Disclosures on record
- 4
No open-market insider trades among the recent disclosures.
SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.
How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session
Bulk & block deals · 30 May 2025
CSV| Date | Deal | Client | Quantity | Price | Value |
|---|---|---|---|---|---|
| 30 May 2025 | Buy · bulk | UTI MUTUAL FUND | 3.67L | 615.37 | ₹22.6Cr |
A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.
Takeover-code disclosures
Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.
Every stock on this session →Short selling, lending & margin
Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.
Exchange surveillance
- P/E > 50 (4 quarters) · since 12 Jan 2026 — P/E above 50 on the last four quarters’ earnings.
Price band: 20% · not in the F&O ban.
From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.
Every stock on this session →Financials · quarterly statement
| Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26AR | Q1 FY27 | Q2 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 220.6 | 217.1 | 244.4 | 222.7 | 217.3 | 237.5 | 172.9 | 193.5 | 207.3 | 368.3 | 304.2 | 341.3 | |
| Other income | 7.6 | 13.4 | 7.6 | 7.5 | 8.5 | 3.9 | 11.4 | 10.8 | 5.6 | 7.8 | 1.8 | 17.8 | |
| Total income | 228.2 | 230.5 | 252.0 | 230.2 | 225.8 | 241.4 | 184.4 | 204.3 | 212.9 | 376.1 | 306.0 | 359.0 | |
| Total expenses | 198.0 | 200.1 | 223.9 | 204.3 | 203.4 | 222.3 | 170.7 | 207.6 | 217.9 | 351.0 | 303.4 | 332.2 | |
| └ Finance costs | 3.5 | 3.5 | 3.5 | 3.3 | 3.8 | 3.9 | 3.3 | 3.7 | 3.2 | 2.0 | 2.2 | 3.6 | |
| └ Depreciation | 9.3 | 8.4 | 8.4 | 8.6 | 8.6 | 8.9 | 8.7 | 8.9 | 9.0 | 10.9 | 10.9 | 11.4 | |
| Profit before tax | 30.2 | 30.4 | 28.1 | 25.9 | 22.5 | 19.1 | 13.7 | (3.3) | (12.1) | 24.8 | 2.6 | 26.8 | |
| Tax expense | 0.0 | (3.1) | (0.2) | 0.0 | 0.0 | (0.0) | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | (0.0) | |
| Net profit | 29.4 | 33.0 | 29.4 | 27.2 | 20.8 | 22.3 | 14.9 | (5.7) | (12.6) | 25.8 | 3.2 | 28.6 | |
| EPS | 6.18 | 6.81 | 5.79 | 5.37 | 4.10 | 4.40 | 2.94 | -1.13 | -2.49 | 4.31 | 0.54 | 4.77 | |
| Net margin | 13.34% | 15.18% | 12.01% | 12.23% | 9.56% | 9.39% | 8.62% | -2.96% | -6.09% | 7.02% | 1.06% | 8.38% | |
| PBT margin | 13.69% | 13.99% | 11.51% | 11.63% | 10.33% | 8.04% | 7.93% | -1.72% | -5.86% | 6.75% | 0.87% | 7.86% | |
| Tax rate | 0.00% | -10.27% | -0.55% | 0.00% | 0.00% | -0.21% | 0.00% | — | — | 0.01% | 2.73% | -0.17% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 14 Nov 2026.
Balance sheet & cash flow · half-yearly
Balance sheet
| FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1,225.2 | 1,492.1 | 1,553.9 | 1,635.1 | 1,687.9 | 1,722.0 | 2,258.4 | 2,652.4 | |
| Current assets | 501.0 | 497.4 | 790.8 | 833.4 | 807.4 | 704.4 | 929.3 | 955.0 | |
| └ Cash & equivalents | 22.6 | 40.4 | 3.6 | 4.4 | 21.1 | 42.0 | 7.1 | 46.6 | |
| └ Other bank balances | 8.0 | 9.9 | 263.0 | 239.5 | 158.5 | 106.5 | 76.4 | 9.6 | |
| └ Current investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Trade receivables | 215.2 | 187.6 | 195.5 | 215.2 | 241.8 | 202.2 | 381.4 | 348.2 | |
| └ Inventories | 228.7 | 222.4 | 264.2 | 320.6 | 326.4 | 306.2 | 372.3 | 422.1 | |
| Total equity | 688.6 | 1,107.8 | 1,169.5 | 1,224.2 | 1,267.3 | 1,273.8 | 1,564.3 | 1,632.3 | |
| └ Attributable to owners | 688.6 | 1,107.8 | 1,169.5 | 1,224.2 | 1,267.3 | 1,273.8 | 1,564.3 | 1,632.3 | |
| └ Non-controlling interest | — | — | — | 0.0 | 0.0 | — | 0.0 | — | |
| └ Share capital | 40.8 | 50.7 | 50.7 | 50.7 | 50.7 | 50.7 | 59.9 | 59.9 | |
| Borrowings | 331.3 | 146.5 | 134.5 | 164.4 | 174.2 | 281.2 | 301.4 | 543.7 | |
| └ Current | 182.5 | 9.9 | 14.0 | 38.5 | 42.6 | 47.2 | 116.7 | 204.6 | |
| └ Non-current | 148.8 | 136.7 | 120.4 | 125.9 | 131.6 | 234.0 | 184.7 | 339.1 | |
| Trade payables | 181.8 | 225.4 | 229.6 | 223.8 | 222.1 | 148.9 | 346.7 | 396.3 | |
| Current liabilities | 371.9 | 239.0 | 260.0 | 281.1 | 285.6 | 210.2 | 491.2 | 652.3 | |
| Total liabilities | 536.6 | 384.2 | 384.4 | 410.9 | 420.6 | 448.2 | 694.1 | 1,020.1 | |
| Net debt | 300.7 | 96.2 | (132.1) | (79.5) | (5.4) | 132.7 | 217.9 | 487.4 | |
| Debt / equity | 0.48 | 0.13 | 0.11 | 0.13 | 0.14 | 0.22 | 0.19 | 0.33 | |
| Current ratio | 1.35 | 2.08 | 3.04 | 2.96 | 2.83 | 3.35 | 1.89 | 1.46 |
Cash flow, year to date
| FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 18.6 | 96.2 | 126.0 | (15.1) | 19.2 | 11.5 | 125.6 | 117.8 | |
| └ Capex | (84.9) | (23.4) | (64.8) | (40.9) | (150.1) | (158.8) | (389.6) | (395.4) | |
| Free cash flow | (66.3) | 72.8 | 61.2 | (56.0) | (130.9) | (147.2) | (264.0) | (277.7) | |
| Investing cash flow | (31.5) | (276.1) | (312.0) | (7.2) | (26.9) | (90.6) | (276.9) | (314.6) | |
| Financing cash flow | 31.2 | 197.8 | 167.0 | 23.1 | 25.2 | 100.0 | 137.1 | 236.3 | |
| └ Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Buybacks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net change in cash | 18.3 | 17.8 | (19.0) | 0.8 | 17.5 | 20.9 | (14.1) | 39.5 |
From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.
Announcements & board meetings
As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.
Every stock on this session →ORCHPHARMA at a glance
- ORCHPHARMA closed at ₹960.4 on 20 Nov 2026, +1.24% on the day, +19.5% over one year, 16.0% below its 52-week high of ₹1,143.5.
- Delivery was 50.5% of traded quantity on 20 Nov 2026, the 23rd percentile of its own 1,495 sessions with a reading (20-session average 43.3%, 1-year average 47.8%).
- Market capitalisation is ₹5,751 crore at a trailing P/E of 127.7 (trailing EPS ₹7.52).
- Q2 FY27 results (consolidated, filed 14 Nov 2026): revenue ₹341 crore (+76.3% year on year), net profit ₹29 crore; the price moved +4.5% on the first session after.
- Promoters held 74.45% at 30 Sept 2026, unchanged on the previous filing.
- Q3 FY27 results are expected between 10 Feb 2027 and 13 Feb 2027, going by past filing dates — an estimate, not an announcement.
About
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.
More in Pharmaceuticals & Biotechnology
- DIDIVISLABDivi's Laboratories Limited11,180.50+0.02%
- LALAURUSLABSLaurus Labs Limited2,294.60-0.49%
- SUSUNPHARMASun Pharmaceutical Industries Limited1,884.90-0.79%
- ACACUTAASAcutaas Chemicals Limited3,833.50-3.61%
- SASAILIFESai Life Sciences Limited1,800.70+0.69%
- PPPPLPHARMAPiramal Pharma Limited239.30-0.15%
- DRDRREDDYDr. Reddy's Laboratories Limited1,390.20-0.76%
- GLGLENMARKGlenmark Pharmaceuticals Limited2,648.00+1.51%
- AUAUROPHARMAAurobindo Pharma Limited1,799.00-0.37%
- CICIPLACipla Limited1,415.00-0.25%
- ZYZYDUSLIFEZydus Lifesciences Limited1,200.00-0.24%
- MAMANKINDMankind Pharma Limited2,665.00+1.37%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE